El interés en corto de Corcept Therapeutics da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Corcept Therapeutics. Los datos de interés en corto se actualizan cada dos semanas.

Corcept Therapeutics (NASDAQ:CORT) Bolsa, Informe de interés en corto

Corcept Therapeutics

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics Inc

CORTS Trust for Bellsouth 7.00% CorTS Ctfs due 12/01/2095

CORTELCO SYS PUERTO RICO by Cortelco Systems Puerto Rico Inc.

Cortelco Systems Puerto Rico Inc

Corteva Inc

Cortex

Cortigent Inc

Structures Products Cp 8% CorTS Issued by Peco Energy Cap Tr II Preferred Stock

Corts Trust Peco Energy Capital Trust III

<ul>
<li>Results from Phase 3 long-term extension study of relacorilant to treat patients with hypercortisolism were presented at the World Congress on Insulin Resistance, Diabetes &amp; Cardiovascular Disease (WCIRDC)</li>
<li>116 patients with hypercortisolism were enrolled with treatment duration of up to six years</li>
<li>Results provide further evidence of relacorilant's potential benefit as a treatment for patients with hypercortisolism</li>
</ul>
Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its Phase 3 long-term, open-label extension study of relacorilant to treat patients with endogenous hypercortisolism (Cushing's syndrome) at the WCIRDC. The results from this study demonstrated that patients treated with relacorilant experienced clinically meaningful and durable cardiometabolic improvements and relacorilant was well-tolerated, with a treatment duration of up to six years.

Biotech

News

General

CORT

Corcept Therapeutics Presents Phase 3 Long-Term Extension Study Of Relacorilant Demonstrated Durable Cardiometabolic Improvements In Patients With Hypercortisolism

On Thursday, Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) said that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym&nbsp;in patients with hypercortisolism (Cushing&#8217;s syndrome) and difficult-to-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42471783/corcept-announces-positive-results-in-treatment-phase-of-catalyst-trial-in-patients-with-hypercort" rel="noreferrer noopener">control type 2 diabetes</a>.
Hypercortisolism is caused by excessive activity of the hormone cortisol. Symptoms vary, but most patients experience one or more of the following manifestations: hypertension, central obesity, elevated blood sugar and difficult-to-control type 2 diabetes, severe fatigue, and weak muscles.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41102063/corcept-therapeutics-commercial-drug-korlym-sales-impress-despite-increased-competi" rel="noreferrer noopener">Corcept Therapeutics&#8217; Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast</a>
CATALYST is a prospective Phase 4 study with two parts. The first part assessed the prevalence of hypercortisolism by screening 1,057 patients with difficult-to-control type 2 diabetes, defined as hemoglobin A1c greater than 7.5% despite receiving optimal therapies, including GLP-1 agonists.
The primary endpoint was the reduction in hemoglobin A1c between these groups. CATALYST met its primary endpoint.
Patients who received Korlym exhibited a clinically meaningful and statistically significant improvement in hemoglobin A1c, with a decrease from baseline of 1.47% compared to a decrease of 0.15% in patients who received a placebo.
Complete results from CATALYST will be presented at a medical conference next year.
The safety profile of Korlym was consistent with the medication&#8217;s label, and no new side effects or adverse events were identified.
In February 2012, the company introduced Korlym, the first medication approved by the FDA to treat patients with endogenous hypercortisolism.
Price Action: CORT stock traded higher by 2.09% at $57.50 premarket at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42470137/t-mobiles-premium-valuation-prompts-downgrade-growth-projections-decelerate" target="_blank" rel="noreferrer noopener">T-Mobile&#8217;s Premium Valuation Prompts Downgrade As Growth Projections Decelerate: Analyst</a></li>
</ul>
Photo via Shutterstock.

Equities

Health Care

Corcept Therapeutics' FDA-Approved Korlym Hits Main Goal In Cushing's Syndrome Patients With Difficult-To-Control Diabetes

Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-controlled study of Korlym&#xAE; in patients with hypercortisolism (Cushing's syndrome) and difficult-to-control type 2 diabetes.
CATALYST is a prospective, Phase 4 study with two parts. The first part assessed the prevalence of hypercortisolism by screening 1057 patients with difficult-to-control type 2 diabetes, defined as hemoglobin A1c greater than 7.5 percent despite receiving optimal therapies, including GLP-1 agonists. Of these patients, 23.8 percent were identified as having hypercortisolism and were eligible to enter CATALYST's treatment phase, in which 136 patients were randomized, 2:1, to receive either Korlym or placebo for 24 weeks. The primary endpoint was the reduction in hemoglobin A1c between these groups.
CATALYST met its primary endpoint. Patients who received Korlym exhibited a clinically meaningful and statistically significant improvement in hemoglobin A1c, with a decrease from baseline of 1.47 percent as compared to a decrease of 0.15 percent in patients who received placebo (placebo-adjusted reduction of 1.32 percent; p-value: &lt; 0.0001). The safety profile of Korlym in this study was consistent with the medication's label and no new side effects or adverse events were identified.
Complete results from CATALYST will be presented at a medical conference next year.

Corcept Announces Primary Endpoint Met In Treatment Phase Of CATALYST Trial In Patients With Hypercortisolism And Difficult-To-Control Diabetes

WIIM

Corcept Therapeutics shares are trading lower after the company announced results from its Phase 2 DAZALS study evaluating two doses of dazucorilant in patients with ALS did not meet its primary endpoint.

Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol, today announced results from the DAZALS study, a randomized, double-blind, placebo-controlled, Phase 2 trial evaluating two doses (150 mg and 300 mg) of its proprietary selective cortisol modulator dazucorilant in patients with ALS. Upon completion of the trial, patients were eligible to enter an open-label, long-term extension study, in which they received 300 mg of dazucorilant.
DAZALS did not meet its primary endpoint, which was the change from baseline in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to those who received placebo. Patients who received dazucorilant experienced substantially more gastrointestinal upset at the onset of treatment than those who received placebo. During the 24-week study, no deaths (0/83) were observed in the 300 mg arm, compared to 5 deaths (5/82) in the placebo group (p-value: 0.02). The open-label, long-term extension study will continue and overall survival will be assessed in March 2025 after all patients have had one year pass since the onset of treatment. Dazucorilant has been granted Fast Track Designation by the U.S. Food and Drug Administration.
Complete results from the DAZALS study will be presented at a medical conference next year.

Corcept Announces Results From Phase 2 Study Of Dazucorilant In Patients With Amyotrophic Lateral Sclerosis; DAZALS Did Not Meet Its Primary Endpoint, Which Was The Change From Baseline In The ALS Functional Rating Scale-Revised In Patients Who Received Dazucorilant Compared To Those Who Received Placebo

Politics

President-Elect Trump Said He Will Not Restrict The Availability Of Abortion Pills -NBC's Meet The Press

Revealing a significant insider sell on November 26, Gary Charles Robb, Chief Business Officer at Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), as per the latest SEC filing.
What Happened: Robb's recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001088856/000095017024131176//Archives/edgar/data/1088856/000095017024131176/0000950170-24-131176-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday unveiled the sale of 2,609 shares of Corcept Therapeutics. The total transaction value is $146,625.
Corcept Therapeutics's shares are actively trading at $59.21, experiencing a up of 1.08% during Wednesday's morning session.
<h3>Unveiling the Story Behind Corcept Therapeutics</h3>
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
<h3>Financial Milestones: Corcept Therapeutics's Journey</h3>
Revenue Growth: Over the 3 months period, Corcept Therapeutics showcased positive performance, achieving a revenue growth rate of 47.69% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Holistic Profitability Examination:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 98.43%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): With an EPS below industry norms, Corcept Therapeutics exhibits below-average bottom-line performance with a current EPS of 0.45.
</li>
</ul>
Debt Management: Corcept Therapeutics's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
In-Depth Valuation Examination:
<ul>
<li>
Price to Earnings (P/E) Ratio: Corcept Therapeutics's current Price to Earnings (P/E) ratio of 46.49 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 10.38 is above industry norms, reflecting an elevated valuation for Corcept Therapeutics's stock and potential overvaluation based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Boasting an EV/EBITDA ratio of 39.89, Corcept Therapeutics demonstrates a robust market valuation, outperforming industry benchmarks.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
While insider transactions should not be the sole basis for making investment decisions, they can play a significant role in an investor's decision-making process.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Exploring Key Transaction Codes</h3>
In the domain of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> frequently turn their focus to those taking place in the open market, as meticulously outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001088856">Check Out The Full List Of Corcept Therapeutics's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;utm_source=benzinga-insights">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Gary Charles Robb Takes Money Off The Table, Sells $146K In Corcept Therapeutics Stock

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Buy and maintains $80 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Corcept Therapeutics, Maintains $80 Price Target

Corcept Therapeutics shares are trading lower. The company reported Q3 financial results.

<h3>Gainers</h3>
<ul>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares moved upwards by 28.8% to $4.2 during Wednesday's after-market session. The market value of their outstanding shares is at $2.3 million. </li>
<li>Alphatec Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATEC#NASDAQ">ATEC</a>) shares increased by 11.21% to $6.25. The market value of their outstanding shares is at $877.9 million. The company's, Q3 earnings came out today. </li>
<li>Estrella Immunopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLA#NASDAQ">ESLA</a>) stock rose 10.79% to $0.9. The market value of their outstanding shares is at $32.8 million. </li>
<li>Envista Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVST#NYSE">NVST</a>) stock rose 9.2% to $21.0. The market value of their outstanding shares is at $3.6 billion. As per the news, the Q3 earnings report came out today. </li>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) stock moved upwards by 7.56% to $2.7. The market value of their outstanding shares is at $9.3 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock moved upwards by 7.5% to $1.29. The company's market cap stands at $91.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) shares fell 16.8% to $39.0 during Wednesday's after-market session. The company's market cap stands at $4.0 billion. The company's, Q3 earnings came out today. </li>
<li>Acadia Healthcare Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACHC#NASDAQ">ACHC</a>) shares decreased by 13.22% to $45.2. The company's market cap stands at $4.1 billion. The company's, Q3 earnings came out today. </li>
<li>Venus Concept (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) stock decreased by 12.77% to $0.34. The company's market cap stands at $2.4 million. </li>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares declined by 7.43% to $1.87. The market value of their outstanding shares is at $7.1 million. </li>
<li>Anixa Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) stock decreased by 6.69% to $3.35. The company's market cap stands at $107.8 million. </li>
<li>Eledon Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELDN#NASDAQ">ELDN</a>) stock fell 6.31% to $3.93. The market value of their outstanding shares is at $162.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ACHC

ANIX

ATEC

CMAX

CTOR

ELDN

ESLA

NVST

TFFP

TNON

VERO

12 Health Care Stocks Moving In Wednesday's After-Market Session

Earnings

Guidance

Corcept Therapeutics Sees 2024 Revenue $675M-$700M Vs $661.059M

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) reported quarterly earnings of $0.41 per share which beat the analyst consensus estimate of $0.28 by 46.43 percent. The company reported quarterly sales of $182.50 million which beat the analyst consensus estimate of $171.97 million by 6.12 percent. This is a 47.65 percent increase over sales of $123.60 million the same period last year.

Earnings Beats

Corcept Therapeutics Q3 2024 GAAP EPS $0.41 Beats $0.28 Estimate, Sales $182.50M Beat $171.97M Estimate

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-10-30. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Corcept Therapeutics will report an earnings per share (EPS) of $0.28.
Corcept Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.09, leading to a 1.12% drop in the share price on the subsequent day.
Here's a look at Corcept Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.23</td>
<td>0.22</td>
<td>0.26</td>
<td>0.21</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.32</td>
<td>0.25</td>
<td>0.28</td>
<td>0.28</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>5.0%</td>
<td>-7.000000000000001%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730217666_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Corcept Therapeutics were trading at $48.34 as of October 28. Over the last 52-week period, shares are up 70.24%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Corcept Therapeutics</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Corcept Therapeutics.
Analysts have given Corcept Therapeutics a total of 4 ratings, with the consensus rating being Buy. The average one-year price target is $75.25, indicating a potential 55.67% upside.
<h3>Analyzing Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Organon, Axsome Therapeutics and Elanco Animal Health, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>The consensus outlook from analysts is an Underperform trajectory for Organon, with an average 1-year price target of $20.0, indicating a potential 58.63% downside.</li>
<li>For Axsome Therapeutics, analysts project an Buy trajectory, with an average 1-year price target of $131.33, indicating a potential 171.68% upside.</li>
<li>The consensus among analysts is an Outperform trajectory for Elanco Animal Health, with an average 1-year price target of $19.0, indicating a potential 60.7% downside.</li>
</ul>
<h3>Overview of Peer Analysis</h3>
Within the peer analysis summary, vital metrics for Organon, Axsome Therapeutics and Elanco Animal Health are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corcept Therapeutics</td>
<td>Buy</td>
<td>39.15%</td>
<td>$161.27M</td>
<td>6.14%</td>
</tr>
<tr>
<td>Organon</td>
<td>Underperform</td>
<td>-0.06%</td>
<td>$939M</td>
<td>203.12%</td>
</tr>
<tr>
<td>Axsome Therapeutics</td>
<td>Buy</td>
<td>86.65%</td>
<td>$79.11M</td>
<td>-64.28%</td>
</tr>
<tr>
<td>Elanco Animal Health</td>
<td>Outperform</td>
<td>12.02%</td>
<td>$689M</td>
<td>-0.83%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Corcept Therapeutics ranks highest in Revenue Growth among its peers. It is at the bottom in terms of Gross Profit. The company is at the bottom in terms of Return on Equity.
<h3>All You Need to Know About Corcept Therapeutics</h3>
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
<h3>Financial Milestones: Corcept Therapeutics's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining Corcept Therapeutics's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 39.15% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Corcept Therapeutics's net margin excels beyond industry benchmarks, reaching 21.44%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 6.14%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Corcept Therapeutics's ROA stands out, surpassing industry averages. With an impressive ROA of 5.13%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.
<a href="https://www.benzinga.com/quote/CORT/earnings">To track all earnings releases for Corcept Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview: Corcept Therapeutics

Across the recent three months, 7 analysts have shared their insights on Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Corcept Therapeutics, presenting an average target of $60.29, a high estimate of $80.00, and a low estimate of $38.00. This current average reflects an increase of 41.16% from the previous average price target of $42.71. 
<img src="https://www.benzinga.com/files/images/story/2024/1729256458_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Corcept Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$80.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$76.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Edward Nash</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Edward Nash</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Corcept Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Corcept Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Corcept Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Corcept Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CORT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Corcept Therapeutics analyst ratings.</a>
<h2>About Corcept Therapeutics</h2>
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
<h3>Financial Insights: Corcept Therapeutics</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Corcept Therapeutics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 39.15%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Corcept Therapeutics's net margin excels beyond industry benchmarks, reaching 21.44%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Corcept Therapeutics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 6.14%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Corcept Therapeutics's ROA excels beyond industry benchmarks, reaching 5.13%. This signifies efficient management of assets and strong financial health.
Debt Management: Corcept Therapeutics's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From Corcept Therapeutics Analyst Ratings

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Buy and raises the price target from $45 to $80.

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $80

Truist Securities raised the price target for Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) and cites continued momentum in Korlym sales more than a decade after launch amid increasing competition and says it &#8220;is impressive and difficult to ignore.&#8221;
Korlym (mifepristone) is a prescription medicine used to treat high blood sugar (hyperglycemia) caused by high cortisol levels in the blood (hypercortisolism) in adults with endogenous Cushing syndrome who have type 2 diabetes mellitus or glucose intolerance and who cannot have surgery or for whom surgery has failed.&nbsp;
Cushing syndrome is&nbsp;a hormonal disorder that occurs when the body has too much cortisol, a hormone that helps the body respond to stress.&nbsp;
Truist analyst notes approximately 20K Cushing&#8217;s disease (pituitary adenoma) patients in the U.S., of which ~10K are adequately managed with surgical resection of the pituitary adenoma.
Medical management is recommended for the remaining 10K. Therefore, there&#8217;s still significant room for growth, with just ~2,000 hypercortisolism patients currently on Korlym.
In June, Teva Pharmaceuticals Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) reportedly sued Corcept Therapeutics, accusing it of a monopoly on Korlym.
The lawsuit, filed in federal court in San Francisco, alleges that Corcept and its sole distributor, Optime Care, engaged in anti-competitive practices <a target="_blank" href="https://www.benzinga.com/24/06/39339275/concerpt-therapeutics-shares-are-trading-lower-what-you-need-to-know" rel="noreferrer noopener">to stifle competition</a>.
In May,&nbsp;Corcept Therapeutics announced that the GRACE Phase 3 trial of&nbsp;relacorilant&nbsp;in patients with hypercortisolism (Cushing&#8217;s syndrome)&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/39039282/why-mid-cap-corcept-therapeutics-stock-trading-higher-on-tuesday" rel="noreferrer noopener">met its primary endpoint</a>.
The company is conducting a Phase 3 GRADIENT trial for relacorilant with enrolled adrenal adenoma patients to strengthen the case for treating patients whose hypercortisolism was driven by adrenal adenoma.
Data from GRACE and GRADIENT studies will form a part of the FDA application submission. The analyst says, &#8220;GRADIENT is well-powered for success.&#8221;
Truist notes that Corcept Therapeutics can achieve around $3 billion in total revenue within five years.
The analyst highlights that management emphasized that once relacorilant is approved, almost all existing patients on Korlym would be converted to relacorilant.
With increased market penetration of relacorilant in Cushing&#8217;s from 16% to 25% in 2033, Truist raised the price target from $65 to $76, <a target="_blank" href="https://www.benzinga.com/quote/CORT/analyst-ratings" rel="noreferrer noopener">with a Buy rating</a>.
Price Action: CORT stock is up 5.19% at $46.21 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41101457/optimism-around-aquestive-as-it-moves-forward-with-severe-allergy-baldness-candidat" target="_blank" rel="noreferrer noopener">Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate</a>.</li>
</ul>

Analyst Color

TEVA

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast

Corcept Therapeutics shares are trading higher after Truist Securities maintained a Buy rating on the stock and raised its price target from $65 to $76.

Truist Securities analyst Joon Lee maintains Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) with a Buy and raises the price target from $65 to $76.

Truist Securities Maintains Buy on Corcept Therapeutics, Raises Price Target to $76

Corcept Therapeutics (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cort#NASDAQ">CORT</a>) shares soared 6.5% in the last trading session to close at $42.27. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock&#39;s 15.7% gain over the past four weeks.
The company&#39;s sole marketed drug, Korlym, approved for treating Cushing&#39;s syndrome, is witnessing strong demand and driving growth. Also, a new drug application for the lead candidate, relacorilant, to treat Cushing&#39;s syndrome is expected to be filed in the fourth quarter of 2024. The ongoing progress with Korlym and relacorilant could be the reason for the share price rally.
This drug developer is expected to post quarterly earnings of $0.26 per share in its upcoming report, which represents a year-over-year change of -7.1%. Revenues are expected to be $171.04 million, up 38.4% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Corcept, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock&#39;s price usually doesn&#39;t keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on CORT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold).
Corcept is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Zoetis (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zts#NYSE">ZTS</a>), finished the last trading session 0.4% higher at $196.48. ZTS has returned 6.6% over the past month.
For Zoetis, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $1.46. This represents a change of +7.4% from what the company reported a year ago. Zoetis currently has a Zacks Rank of #2 (Buy).
<a href="https://www.zacks.com/stock/news/2338319/corcept-cort-moves-6-5-higher-will-this-strength-last?cid=CS-BENZ-FT-tale_of_the_tape|daily_price_change_5%-2338319">To read this article on Zacks.com click here.</a>

Mid Cap

Markets

Corcept Moves 6.5% Higher: Will This Strength Last?

In the preceding three months, 6 analysts have released ratings for Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $50.17, a high estimate of $78.00, and a low estimate of $35.00. This upward trend is apparent, with the current average reflecting a 34.4% increase from the previous average price target of $37.33.
<img src="https://www.benzinga.com/files/images/story/2024/1726693276_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The standing of Corcept Therapeutics among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Edward Nash</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Edward Nash</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Corcept Therapeutics. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Corcept Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Corcept Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Corcept Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CORT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Corcept Therapeutics analyst ratings.</a>
<h2>Unveiling the Story Behind Corcept Therapeutics</h2>
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
<h3>Unraveling the Financial Story of Corcept Therapeutics</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Corcept Therapeutics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 39.15%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Corcept Therapeutics's net margin excels beyond industry benchmarks, reaching 21.44%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Corcept Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 6.14%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Corcept Therapeutics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 5.13%, the company showcases efficient use of assets and strong financial health.
Debt Management: Corcept Therapeutics's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 6 Analyst Projections For Corcept Therapeutics

BlackRock Advantage Small Cap Core Fund Q3 2024 Commentary

Trump Media saw the largest increase in short interest in October

Corcept Therapeutics: A Most Promising And Compelling Biotech

Corcept Therapeutics (CORT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Edward Nash...

Positive Outlook for Corcept Therapeutics Amid Phase III Delays and Market Opportunities for Relacorilant

Corcept Therapeutics (CORT) Incorporated announced results from the DAZALS study, a randomized, double-blind, placebo-controlled, Phase 2 trial eva...

Corcept says DAZALS study did not meet primary endpoint

Corcept Phase 2 study of ALS drug fails to meet primary endpoint

Canaccord Genuity analyst Edward Nash has maintained their bullish stance on CORT stock, giving a Buy rating on December 6. Edward Nash's rating is...

Optimistic Outlook for Corcept Therapeutics Amid Promising Developments and Regulatory Advantages

Corcept Therapeutics (CORT) announced that the primary endpoint was met in the treatment phase of CATALYST, a randomized, double-blind, placebo-con...

Corcept Therapeutics says CATALYST trial met primary endpoint

Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company's shares closed yesterday at $56.33. According to TipRanks,...

Corcept Therapeutics (CORT) Receives a Buy from Truist Financial

Corcept Therapeutics (CORT) presented results from its Phase 3 long-term, open-label extension study of relacorilant to treat patients with endogen...

Corcept Therapeutics presents results from relacorilant study

ACIW

AMKR

AMTM

BIRK

CART

CELH

DOCU

ENPH

ENSG

EXLS

FOUR

LCID

LINE

MDGL

NTRA

ODFL

OLLI

ONTO

PAGP

RIVN

SIRI

SMMT

SWKS

UFPI

UPST

VERX

VRNS

Press Releases

Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association's Scientific Sessions

FDA move illuminates key role of telomere targeting as a viable therapeutic strategy for cancer treatment

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT)

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate Update

Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS)

Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing's Syndrome) and Difficult-to-Control Diabetes

Corcept's Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

ADMA

HALO

MAIA

UTHR

VRTX

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Corcept Therapeutics

Interés en corto

Corcept Therapeutics (NASDAQ:CORT) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL